fluticasone + montelukast + procaterol

This is a combination drug containing three active pharmaceutical ingredients used primarily in the management of asthma and related respiratory conditions: - **Fluticasone** is an inhaled synthetic corticosteroid that acts as an anti-inflammatory agent, reducing airway inflammation and hyperresponsiveness. - **Montelukast** is a leukotriene receptor antagonist that blocks leukotriene D4 at the cysteinyl leukotriene receptor in the lungs, leading to decreased bronchoconstriction and inflammation. - **Procaterol** is a short-acting beta-2 adrenergic agonist (SABA) bronchodilator that relaxes bronchial smooth muscle, providing rapid relief from acute bronchospasm. The combination aims to provide comprehensive asthma control by addressing both chronic airway inflammation (fluticasone), leukotriene-mediated symptoms (montelukast), and acute bronchoconstriction (procaterol). While combinations of fluticasone with montelukast are well-studied for improving clinical efficacy in asthma[1][3][6], there is limited published evidence on triple fixed-dose combinations including procaterol. Each component has established roles in guideline-based asthma therapy.